# Quetiapine Extended Release (XR) in Bipolar Patients With Comorbid Generalized Anxiety Disorder (GAD)

> **NCT00671853** · PHASE3 · COMPLETED · sponsor: **University Hospitals Cleveland Medical Center** · enrollment: 120 (actual)

## Conditions studied

- Bipolar Disorder
- Anxiety
- Anxiety Disorders
- Substance Use Disorders

## Interventions

- **DRUG:** Quetiapine XR
- **DRUG:** Placebo for quetiapine XR

## Key facts

- **NCT ID:** NCT00671853
- **Lead sponsor:** University Hospitals Cleveland Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2016-12-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00671853

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00671853, "Quetiapine Extended Release (XR) in Bipolar Patients With Comorbid Generalized Anxiety Disorder (GAD)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00671853. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*